Wall Street Zen Upgrades Insulet (NASDAQ:PODD) to Buy

Insulet (NASDAQ:PODD) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. restated a “neutral” rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Insulet in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price objective on the stock. Stifel Nicolaus lowered their target price on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wells Fargo & Company cut shares of Insulet from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $255.00 to $144.00 in a research report on Wednesday, August 5th. Finally, Sanford C. Bernstein dropped their target price on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $193.48.

Insulet Stock Performance

Insulet stock opened at $135.28 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a market cap of $9.38 billion, a PE ratio of 25.29, a PEG ratio of 1.07 and a beta of 1.11. The company’s 50-day moving average is $141.73 and its two-hundred day moving average is $159.17.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter last year, the firm earned $1.17 EPS. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts anticipate that Insulet will post 6.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Insulet during the second quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership lifted its holdings in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Man Group plc purchased a new stake in shares of Insulet in the second quarter worth about $78,746,000. Amundi grew its position in shares of Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after purchasing an additional 60,929 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in Insulet during the second quarter worth about $64,921,000.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.